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Clinical characteristics and treatment
outcomes in a cohort of patients with
pyogenic and amoebic liver abscess
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and Alastair C. McGregor1,3,4
Abstract
Background: We describe the clinical features of a cohort of patients with liver abscesses and investigate
relationships between clinical, radiological and microbiological findings and mortality.
Methods: Retrospective review of pyogenic (PLA) or amoebic liver abscesses (ALA) diagnosed and treated at a
major infectious diseases department in London over 9 years.
Results: One hundred forty-one patient records were identified; 132 (93.6%) had PLA and 9 (6.4%) ALA. No
organism was identified in 38.6% (51/132); a single bacterial species was isolated in 47.0% (62/132) of PLA, ≥ 2 in
14.4% (19/132). There was weak evidence of variation in abscess size by type of microorganism, with streptococcal
PLA typically larger (p = 0.03 for Streptococcus milleri group, p = 0.05 for non-milleri streptococci). Patients with ALA
were younger (median 41, IQR 37–51 years) than those with PLA (median 68, IQR 50.5–78 years) (p = 0.003) and all
were male (9/9, 100%, (p = 0.03)), with a history of recent travel in the majority (6/9, 66.7% (p = 0.003)). C-
reactive protein was higher in ALA than in PLA (p = 0.06). In the entire cohort, loculation (HR = 2.51 (95% CI
1.00–6.32), p = 0.04) and baseline ALP (HR = 4.78 (95% CI 1.19–19.2) per log10 increase, p = 0.03) were
associated with mortality. 16S ribosomal RNA (rRNA) analysis was used in a subset of culture-negative cases
and increased the diagnostic yield by 13%.
Conclusions: Clinical or radiological features cannot be used to distinguish between PLA and ALA, or help
identify the bacterial cause of PLA. However, ALA is more common in young, male patients with a history of
travel. 16S rRNA analysis of abscess fluid has a role in improving microbiological diagnosis in culture-negative
cases.
Keywords: Liver abscess, Amoebic liver abscess, Pyogenic liver abscess, 16S ribosomal RNA, Risk factors,
Treatment outcome, Hospital mortality
Background
The incidence of liver abscess, a rare but potentially life-
threatening infection, appears to be increasing world-
wide [1–4]. The use of antibiotics, imaging and less inva-
sive procedures for source control have improved
treatment outcomes over the last century, but mortality
remains high [1, 5, 6] At present, there are no national
or international clinical guidelines, and limited evidence
to guide decisions about care.
A wide variety of bacteria have been described as
causes of pyogenic liver abscess (PLA), but published
data on associations of bacterial species with clinical
presentation, radiological findings and prognosis are
sparse. Entamoeba histolytica, a protozoan parasite, is
also a well-recognized non-bacterial cause of liver ab-
scess. In Europe, cases of amoebic liver abscess (ALA)
are rare and usually imported, whereas in some highly
endemic areas ALA can be more common than PLA [7].
There is good evidence that ALA can be treated
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successfully with shorter courses of antimicrobial ther-
apy than PLA, and that drainage is generally not re-
quired [8]. However, there is limited evidence as to how
PLA and ALA can be distinguished clinically or
radiologically.
In this study we describe a cohort of liver abscess pa-
tients treated at a large infectious diseases department
over a 9-year period and report the clinical characteris-
tics and treatment outcomes of PLA and ALA.
Methods
Setting and patients
We conducted a retrospective case note review of all
adult liver abscess patients treated at our hospital
(Northwick Park Hospital, Middlesex, UK) between May
2008 and June 2017. Patients presenting with liver ab-
scess were identified using a prospectively recorded
database of infectious disease inpatients, as well as a
retrospective search of clinical coding data (search term
“liver abscess”, ICD 10 code = K750). Data collected
from the hospital electronic patient information systems
included patient characteristics (age, sex, ethnicity),
medical background and comorbidities, the results of
standard biochemical and haematological tests on ad-
mission (full blood count, C-Reactive Protein (CRP), ala-
nine transaminase (ALT), alkaline phosphatase (ALP)
and bilirubin), the characteristics of the abscess (isolated
microorganism(s) and resistance patterns, number of ab-
scesses, maximum diameter and loculation), and treat-
ment outcome (antibiotic use, use of aspiration,
discharge, death).
Management of liver abscess
In the absence of consensus guidelines, patients with
liver abscesses were investigated and managed at the dis-
cretion of the attending physician. Abscesses were iden-
tified by ultrasound or computed tomography. Samples
submitted to the microbiology lab (abscess pus, blood
cultures) were processed according to national guide-
lines (British Society of Antimicrobial Chemotherapy
(BSAC), until February 2016, then European Committee
on Antimicrobial Susceptibility Testing (EUCAST)) in a
CPA (Clinical Pathology Accreditation) accredited la-
boratory. The choice of antimicrobial agents was guided
by infection specialists. In a subset of cases, aspirates
were sent for 16S ribosomal RNA (rRNA) sequencing
(Great Ormond Street Hospital, in-house assay).
Amoebic serology was performed when there was clin-
ical suspicion of E. histolytica infection (in-house im-
munofluorescent antibody test (IFAT) and Cellulose
Acetate Precipitin (CAP), Department of Parasitology,
Hospital for Tropical Diseases, London).
Statistical analysis
Characteristics of pyogenic and amoebic abscesses were
compared using Fisher’s exact and Kruskal-Wallis tests
for categorical and continuous variables, respectively
(α = 0.05). Differences in clinical characteristics and
treatment outcome (death within 30 days, and death
within 6 months) by type of isolated microorganism were
tested using a Wald-type test (F statistic) of Somers’ D
parameters for continuous variables (adjusted for within-
patient clustering) or Fisher’s exact tests for categorical
variables. Associations of type of microorganism with
all-cause mortality (within 30 days and within 6
months of admission) were investigated by fitting
random-effects parametric survival-time models with
patient as the panel variable and standard errors ad-
justed for within-patient clustering. Risk factors for 6-
month all-cause mortality were investigated using Cox
regression models. Variables for which there was evi-
dence (p ≤ 0.1) suggestive of an association in univari-
ate models were carried forward to a multivariable
model, from which variables were eliminated by mu-
tual adjustment to obtain a final model of independ-
ently associated (p ≤ 0.05) risk factors.
Results
Characteristics of PLA and ALA patients
We identified 132 pyogenic liver abscess (PLA) and 9
amoebic liver abscess (ALA) admissions during the
period May 2008 to June 2017 (Table 1). PLA patients
were representative of the ethnically diverse local popu-
lation: 47/132 (35.6%) identified as “White (British/
other)”; 33/132 (25%) as “Indian/Pakistani”; and 19/132
(14.4%) as “Other Asian”. All but one of the ALA pa-
tients was from an “Indian/Pakistani” (5/9, 55.6%) or
“Other Asian” background (3/9, 33.3%).
ALA patients were younger (median 41, IQR 37–51
years) than PLA patients (median 68, IQR 50.5–78
years) (p = 0.003), and all ALA patients were male
compared with 63.6% (84/132) of PLA patients (p =
0.03). 66.7% (6/9) of ALA patients had documentation
of recent travel (< 1 year) compared to only 21.1%
(23/132) of PLA patients (p = 0.003). Coexisting dia-
betes mellitus was recorded for 27.3% (36/132) of
PLA and 33.3% (3/9) of ALA patients. Eighteen PLA
patients (13.6%) and none of the ALA patients were
classed as immunocompromised in the preceding
year. None of the patients were known to be HIV
positive.
Radiological characteristics of PLA and ALA
There were no differences in the radiological character-
istics of ALA compared with PLA: multiple abscesses,
ALA 22.2% (2/9), PLA 43.2% (57/132), p = 0.30; max-
imum diameter, ALA median 7.3 cm (IQR 5.8–8.8 cm),
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PLA 6.1 cm (4.8–9.0 cm), p = 0.50; loculation, ALA
11.1% (1/9), PLA 39.4% (52/132), p = 0.15, or position,
ALA right sided abscess 77.8% (7/9), PLA 68.6% (81/
118), p = 0.7 (Additional file 1: Table S1).
PLA microbiology
Organisms were identified via culture from peripheral
blood (33/132, 25%) or from pus aspirated from the ab-
scesses (45/132, 34%) or from both. 16S rRNA gene
Table 1 Characteristics of patients (N = 141) by type of liver abscess (pyogenic or amoebic)
Pyogenic
(n = 132)
Amoebic
(n = 9)
Sex Male 84 (63.6%) 9 (100.0%)
Age (years) Median (IQR) 68 (51–78) 41 (37–51)
Ethnicity White (British or Other) 47 (35.6%) 1 (11.1%)
Indian/Pakistani 33 (25.0%) 5 (55.6%)
Asian 19 (14.4%) 3 (33.3%)
Other 17 (12.9%) 0 (0.0%)
Caribbean 13 (9.9%) 0 (0.0%)
African 3 (2.3%) 1 (11.1%)
Number of organismsa 0 51 (38.6%) –
1 62 (47.0%) –
2 9 (6.8%) –
3 8 (6.1%) –
4 2 (1.5%)
Organism None 51 (38.6%) –
Grouped for analysis Enterobacteriaceae 14 (10.6%) –
E. Coli 21 (15.9%)
Klebsiella spp. 21 (15.9%)
S. milleri group 19 (14.4%) –
Other Strep spp. 7 (5.3%)
Anaerobe 16 (12.1%) –
Grouped as ‘other’ for analysis Enterococcus 5 (3.8%)
Staphylococcus aureus 1 (0.8%) –
Pseudomonas aeriginosa 2 (1.5%) –
Other (Anaeroglobus, Haemophilus,
Corynebacterium, Sutterella)
5 (3.8%) –
Number of abscesses identified 1 75 (56.8%) 7 (77.8%)
2 19 (14.4%) 1 (11.1%)
≥3 38 (28.8%) 1 (11.1%)
Maximum diameter (cm) Median (IQR) 6.1 (4.8–9.0),
n = 118
7.3 (5.8–8.8),
n = 8
Loculated 52 (39.4%) 1 (11.1%)
Antimicrobial resistanceb 45 (34.1%) –
Abscess aspirated/drained 79 (59.9%) 6 (66.7%)
Diabetic 36 (27.3%) 3 (33.3%)
Recent travel (< 1 year) 23 (21.1%) 6 (66.7%)
Immunosuppression (chemotherapy, steroids, immunotherapy or
combination in previous year)
18 (13.6%) 0 (0.0%)
Died within 30 days 7 (5.3%) 0 (0.0%)
Died within 6 months 20 (15.2%) 0 (0.0%)
ain total, 111 microorganisms were isolated from 81 pyogenic liver abscess patients
bResistance was detected to one or more antimicrobial agents in 45/132 patients and in 54/111 (48.7%) of microorganisms
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sequencing was available from early 2015, and was per-
formed on 17 abscesses, giving a positive result in 14
cases; in 9/14 cases it was the only method by which an
organism was identified (Additional file 1: Table S2). A
single bacterial species was isolated in 47.0% (62/132) of
PLA. Multiple pathogens were identified in 19/132
(14.4%). In 51/132 (38.6%), no microbiological cause was
found. The most common bacteria identified were:
Escherichia coli (15.9%, 21/132); Klebsiella spp. (15.9%,
21/132); and Streptococcus milleri group (14.4%, 19/132)
(Table 1).
Clinical characteristics by type of microorganism
There was weak evidence for overall variation in size
(p = 0.04) and loculation (p = 0.09) of abscesses by type
of microorganism (Table 2). Abscesses caused by
streptococci (S. milleri group and non-milleri strepto-
cocci) tended to be larger than those caused by other
microorganisms (Somers’ D p = 0.03 for S. milleri, p =
0.05 for non-milleri streptococci). Abscesses with no iso-
lated microorganism tended to be smaller (p = 0.04).
There were no overall associations between specific mi-
croorganisms and baseline biochemical measurements
(Table 2), but compared with all other microorganism:
Enterobacteriaceae (including E. coli) and S. milleri were
associated with lower ALT (Somers’ D p = 0.03 and p =
0.05, respectively), and Klebsiella with higher ALT (p <
0.001). ALA tended to be associated with higher CRP
(p = 0.06).
Treatment
73.7% (87/118) of PLA had a diameter ≥ 5 cm, compared
with 87.5% (7/8) of ALA (p = 0.68). Overall, 76.3% (71/
93) of abscesses ≥5 cm were drained, compared with
25.0% (8/32) of abscesses < 5 cm. There were 26 ab-
scesses ≥10 cm in diameter, including 1 amoebic abscess.
In total, 78 (59.1%) of PLA had aspiration/therapeutic
drainage, and 9 (6.9%) required a repeat aspiration/
drainage. Seven PLA patients (5.3%) required open sur-
gical drainage; 6/9 (66.7%) ALA patients had an aspir-
ation/drainage of their abscess, but none required
further intervention. Length of stay was much shorter
for ALA (median 7, IQR 6–9 days) than PLA patients
(median 17, IQR 10–29 days) (p = 0.004). Antibiotic
treatment in the PLA group was continued for a median
of 53 days and needed changing at least once in 79.5%
(105/132) of patients, two or more times in 34.1% (45/
132). Antimicrobial resistance was detected in 34.1%
(45/132) of patients, and in 48.7% (54/111) of isolated
microorganisms, almost exclusively in enterobacteria-
ceae (74.3% (26/35)) and Klebsiella (71.4% (15/21)). Re-
sistance in the PLA group to the most commonly used
first line empiric antibiotics; co-amoxiclav, piperacillin/
tazobactam and metronidazole was 12.1% (16/132), 1.5%
(2/132) and 0% respectively (Table 2).
Associations of type of microorganism and other factors
with death
There were no deaths in the ALA group, compared to
5.3% (7/132) 30-day mortality and 15.2% (20/132) 6-
month mortality in the PLA group. Two of the seven
30-day deaths and 4/20 6-month deaths were patients
with biliary malignancy. There were no associations be-
tween type of microorganism and all-cause mortality
within 30 days or 6 months (Additional file 1: Table S3).
In univariate analyses, only age was associated with
death < 6months (hazard ratio (HR) = 1.05 (95% CI 1.02,
1.09) per year increase, p = 0.003). Loculation, baseline
anaemia (Hb < 110 g/L), baseline ALP, and immunosup-
pression (chemotherapy, steroids, immunotherapy) met
the criteria (p ≤ 0.1) for evaluation by multivariable ana-
lysis. Loculation (HR = 2.51 (95% CI 1.00, 6.32), p = 0.04)
and baseline ALP (HR = 4.78 (95% CI 1.19, 19.2) per
log10, i.e. tenfold, increase, p = 0.03) (Additional file 1:
Table S4) were independently associated with mortality
when mutually adjusted.
Discussion
In our cohort of patients with liver abscess we found no
large differences in clinical parameters between pyogenic
liver abscess (PLA) and amoebic liver abscess (ALA),
other than weak evidence of higher baseline C-Reactive
Protein (CRP) for ALA compared with PLA. PLA pa-
tients had a 6-month mortality of 15.2% (20/132),
whereas no ALA patients died. We found that strepto-
cocci were associated with larger abscesses than other
bacteria. Baseline ALP and loculation, but not type of
microorganism, were associated with increased risk of 6-
month all-cause mortality in the PLA group.
Previous studies comparing pyogenic and amoebic ab-
scesses have attempted to identify features that distin-
guish the two, other than travel history [7, 9–12]. Many
reports have shown a preponderance of ALA in male pa-
tients, who also tend to be younger than patients with
PLA [4, 6, 9–18]. Others have documented differences
in shape, position and echogenicity on ultrasonography
that suggest ALA over PLA [10, 12, 19, 20]. Our results
are consistent with the epidemiology described in these
earlier papers, as all of our ALA patients were male and
had a median age 30 years younger than the PLA patient
group. As in other studies, all 9 ALAs in our cohort in-
volved the right lobe (2 also involved the left). We also
found that CRP was higher in ALA than in PLA, al-
though this result is unlikely to assist in differentiating
these entities.
Half (47%) of PLAs in our study were monomicrobial,
and the most common bacterial isolates (found in
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roughly equal proportions) were E. coli, S. milleri group
and Klebsiella species, consistent with results from a
number of other studies [1, 16, 17, 21, 22]. Culture of
fluid obtained by cyst aspiration provided a microbio-
logical diagnosis in 34% of cases, whereas blood culture
was only positive in 25%. Given the importance of En-
terobacteriaceae as etiologic agents in PLA, and the as-
sociated problems of antibiotic resistance, aspiration for
diagnostic purposes would appear to be a crucial tool in
optimising management. There is also likely to be a role
for routine testing of culture-negative aspirates with
newer molecular techniques such as PCR amplification
and sequencing of the 16S ribosomal RNA (rRNA) gene.
This has been shown to be more sensitive than trad-
itional culture methods [23, 24], particularly when anti-
biotics have been administered [25]. In our cohort, 16S
rRNA PCR was the only method resulting in a microbio-
logical diagnosis in 9/14 (64.2%) cases in which it was
used. Overall, this technique increased pathogen detec-
tion by 13% and only 3/17 (17.6%) samples were nega-
tive. Although 16S rRNA analysis does not provide
antibiotic susceptibility data, the risk of resistance can
be inferred from the identity of the pathogen. Associa-
tions between radiological features and type of organism
were weak, although we did find that abscesses caused
by streptococci tended to be larger than abscesses
caused by other bacterial species.
Biliary abnormalities are estimated to be responsible
for 30–50% of cases of PLA and are more common than
those related to portal pyaemia, or haematogenous or
direct spread from an adjacent viscus [5, 12, 26–28]. In
our cohort, a biliary source was demonstrated in only
18/132 (13.6%). The reason biliary sources were less
common in our cohort than in other series is not clear.
Diabetes appears to be a major risk factor for developing
PLA, and is associated with severe disease [29–31].
About 30% of our patients with both ALA and PLA
were diabetic and it is possible that cases in this group
are over-represented in our cohort. The source of infec-
tion remains unclear in significant number of PLAs [1,
15, 16] and we were unable to demonstrate a source of
infection in almost 40%. A source of particular concern
is GI malignancy, as these can easily be missed on initial
imaging and reports have documented occult colonic
malignancies in approximately 24% of cryptogenic PLAs,
suggesting that luminal imaging or colonoscopy should
be seriously considered in individuals with PLA without
an obvious source [32].
Mortality rates from PLA have declined over time [5,
33]. Recent retrospective studies report mortalities be-
tween 0 and 13%, although length of follow up varies
and often only in-hospital mortality is reported [1, 15,
34–40]. The 30-day and 6month mortality rates in our
cohort were 5.3 and 15.2% respectively, which are
similar to outcomes in other units. Numerous studies
have attempted to describe predictors of mortality in
PLA; advanced age, leucocytosis, hyperbilirubinaemia,
underlying malignancy, biliary aetiology, diabetes, ab-
scess diameter ≥ 5 cm and underlying organism have all
been suggested as risk factors [5, 22, 41–47]. In our
study, only baseline ALP and the presence of loculation
were predictive of mortality.
Along with antibiotic therapy, options for treatment of
PLA include percutaneous aspiration, percutaneous
drainage and open surgical drainage. There have been
no trials that have compared these different treatment
strategies. In our group, 60% of cases were managed
with aspiration or drainage in addition to antibiotic ther-
apy (76.3% of large (> 5 cm) abscesses vs. 25% of small
(< 5 cm) abscesses). Seven (5.3%) of our PLAs required
surgical drainage. It is unclear how percutaneous or sur-
gical drainage affected outcomes. Antibiotic treatment
was altered at least once in 79.5% of PLA patients (more
than twice in 34.1%), some due to antibiotic resistance,
with 34.1% of patients growing a resistant organisms, in-
cluding 12.1% resistance to one of the most commonly
used empiric antibiotic, co-amoxiclav, but others will
have been altered empirically due to deterioration of the
patient. This observation underlines the importance of
early pathogen identification in order to optimise
management.
Conclusions
There is little quality evidence to guide optimal manage-
ment of PLA. Using a well-characterised cohort of liver
abscess patients, we found some correlations between
organism, clinical features and outcomes of treatment.
The heterogeneity of this cohort of liver abscesses, as
with others in the literature, means that associations
may have been missed and that those identified, such as
higher CRP in ALAs and larger size in PLAs caused by
streptococci, are too subtle to be of use to clinicians.
These findings emphasise the need for a microbiological
diagnosis, which is most effectively obtained by culture
of aspirate fluid. We found 16 s rRNA gene PCR useful
in the identification of bacteria in culture negative
samples. Newer molecular technologies such high-
throughput sequencing may, in the future, further im-
prove the sensitivity of nucleic acid amplification tests
and may also provide antibiotic susceptibility data and
this is likely to lead to improved outcomes for individ-
uals with these infections.
Additional file
Additional file 1: 4 tables showing additional supporting statistical
analysis of data described in main manuscript. (DOCX 30 kb)
Neill et al. BMC Infectious Diseases          (2019) 19:490 Page 6 of 8
Abbreviations
ALA: Amoebic liver abscess; ALP: Alkaline phosphatase; ALT: Alanine
transferase; BSAC: British Society of Antimicrobial Chemotherapy;
CAP: Cellulose Acetate Precipitin; CPA: Clinical Pathology Accreditation;
EUCAST: European Committee on Antimicrobial Susceptibility Testing;
IFAT: Immunofluorescent antibody test; PLA: Pyogenic liver abscess;
rRNA: Ribosomal RNA
Authors’ contributions
AMcG and DH planned and designed the study, with advice from GGR. LN,
FE and DW collected and prepared the data. SMC performed the analyses.
DH and LN performed the literature search. All authors were involved in
interpretation of results, drafting and revision of the manuscript, and
approved the final version.
Funding
This study did not receive funding.
Availability of data and materials
The data on which this study was based can be made available by the
corresponding author to bone fide researchers subject to appropriate ethical
approvals.
Ethics approval and consent to participate
Our work was done as part of a clinical audit of service delivery on
pseudonymised data supplied by clinical coding and from an internal
database and ethical approval was not required.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Infectious Diseases and Tropical Medicine, London North
West Healthcare NHS Trust, Northwick Park Hospital, Middlesex, Harrow HA1
3UJ, UK. 2Healthcare-Associated Infection & Antimicrobial Resistance Division,
National Infection Service, Public Health England, 61 Colindale Avenue,
London NW9 5EQ, UK. 3Department of Microbiology, London North West
Healthcare NHS Trust, Northwick Park Hospital, Middlesex, Harrow HA1 3UJ,
UK. 4Department of Medicine, Imperial College London, London, UK.
Received: 13 February 2019 Accepted: 23 May 2019
References
1. Lo JZ, Leow LJ, Ng PL, Lee HQ, Mohd Noor NA, Low JK. Predictors of
therapy failure in a series of 741 adult pyogenic liver abscesses. J
Hepatobiliary Pancreat Sci. 2015;22(2):156–65.
2. Tsai FC, Huang Y, Chang LY, Wang JT. Pyogenic liver abscess as endemic
disease, Taiwan. Emerg Infect Dis. 2008;14(10):1592–600.
3. Jepsen P, Vilstrup H, Schonheyder HC, Sorensen HT. A nationwide study of
the incidence and 30-day mortality rate of pyogenic liver abscess in
Denmark, 1977–2002. Aliment Pharmacol Ther. 2005;21(10):1185–8.
4. Meddings L, Myers R, Hubbard J, Shaheen AA, Laupland KB, Dixon E, Coffin
C, Kaplan GG. A population-based study of pyogenic liver abscesses in the
United States: incidence, mortality, and temporal trends. Am J
Gastroenterol. 2010;105(1):117–24.
5. Huang CJ, Pitt HA, Lipsett PA, Osterman FA, Lillemoe K, Cameron JL,
Zuidema GD. Pyogenic hepatic abscess: changing trends over 42 years. Ann
Surg. 1996;223(5):600–9.
6. Rahiman J, Wilson T, Oram V, Holzman RS. Pyogenic liver abscess: recent
trends in etiology and mortality. Clin Infect Dis. 2004;39(11):1654–9.
7. Menon AR, Kizhakkekarammal PK, Rao GK. Amoebic vs pyogenic liver
abscesses: a comparative study in a tertiary care hospital. J Academy Clin
Microbiol. 2015;17(2):89–93.
8. Stanley SL. Amoebiasis. Lancet. 2003;361(9362):1025–34.
9. Barnes PF, De Cock KM, Reynolds TN, Ralls PW. A comparison of amebic and
pyogenic abscess of the liver. Medicine (Baltimore). 1987;66(6):472–83.
10. Lodhi S, Sarwari AR, Muzammil M, Salam A, Smego RA. Features
distinguishing amoebic from pyogenic liver abscess: a review of 577 adult
cases. Tropical Med Int Health. 2004;9(6):718–23.
11. Cosme A, Ojeda E, Zamarreño I, Bujanda L, Garmendia G, Echeverría MJ,
Benavente J. Pyogenic versus amoebic liver abscesses. A comparative
clinical study in a series of 58 patients. Rev Esp Enferm Dig.
2010;102(2):90–9.
12. Conter RL, Pitt HA, Tompkins RK, Longmire WP. Differentiation of pyogenic
from amebic hepatic abscesses. Surg Gynecol Obstet. 1986;162(2):114–20.
13. Mohsen AH, Green ST, Read RC, McKendrick MW. Liver abscess in adults: ten
years experience in a UK centre. QJM. 2002;95(12):797–802.
14. Lee KT, Wong SR, Sheen PC. Pyogenic liver abscess: an audit of 10 years’
experience and analysis of risk factors. Dig Surg. 2001;18(6):459–65
discussion 65-6.
15. Pang TC, Fung T, Samra J, Hugh TJ, Smith RC. Pyogenic liver abscess: an
audit of 10 years’ experience. World J Gastroenterol. 2011;17(12):1622–30.
16. Bosanko NC, Chauhan A, Brookes M, Moss M, Wilson PG. Presentations of
pyogenic liver abscess in one UK centre over a 15-year period. J R Coll
Physicians Edinb. 2011;41:13–7.
17. Petri A, Hohn J, Hódi Z, Wolfárd A, Balogh A. Pyogenic liver abscess -- 20
years’ experience. Comparison of results of treatment in two periods.
Langenbeck's Arch Surg. 2002;387:27–31.
18. Abbas MT, Khan FY, Muhsin SA, Al-Dehwe B, Abukamar M, Elzouki AN.
Epidemiology, clinical features and outcome of liver abscess: a single
reference center experience in Qatar. Oman Med J. 2014;29(4):260–3.
19. Pritt BS, Clark CG. Amebiasis. Mayo Clin Proc. 2008;83(10):1154–9 quiz 9-60.
20. Ralls PW, Barnes PF, Radin DR, Colletti P, Halls J. Sonographic features of
amebic and pyogenic liver abscesses: a blinded comparison. AJR Am J
Roentgenol. 1987;149(3):499–501.
21. Chen SC, Huang C, Tsai SJ, Yen CH, Lin DB, Wang PH, Chen CC, Lee MC.
Severity of disease as main predictor for mortality in patients with pyogenic
liver abscess. Am J Surg. 2009;198(2):164–72.
22. Alvarez Pérez JA, Gonzalez JJ, Baldonedo RF, Sanz L, Carreño G, Junco A,
Rodriguez JI, Martinez MD, Jorge JI. Clinical course, treatment, and
multivariate analysis of risk factors for pyogenic liver abscess. Am J Surg.
2001;181:177–86.
23. Huse SM, Ye Y, Zhou Y, Fodor AA. A core human microbiome as viewed
through 16S rRNA sequence clusters. PLoS One. 2012;7(6):e34242.
24. Song YG, Shim SG, Kim KM, Lee DH, Kim DS, Choi SH, Song JY, Kang HL,
Baik SC, Lee WK, Cho MJ, Rhee KH. Profiling of the bacteria responsible for
pyogenic liver abscess by 16S rRNA gene pyrosequencing. J Microbiol. 2014;
52(6):504–9.
25. Sibley CD, Church D, Surette MG, Dowd SE, Parkins MD. Pyrosequencing
reveals the complex polymicrobial nature of invasive pyogenic infections:
microbial constituents of empyema, liver abscess, and intracerebral abscess.
Eur J Clin Microbiol Infect Dis. 2012;31:2679–91.
26. Krige JE, Beckingham IJ. ABC of diseases of liver, pancreas, and biliary
system. BMJ. 2001;322(7285):537–40.
27. Tsai MS, Lee HM, Hsin MC, Lin CL, Hsu CY, Liu YT, Kao CH. Increased risk of
pyogenic liver abscess among patients with colonic diverticular diseases: a
Nationwide cohort study. Medicine (Baltimore). 2015;94(49):e2210.
28. Mavilia MG, Molina M, Wu GY. The evolving nature of hepatic abscess: a
review. J Clin Transl Hepatol. 2016;4(2):158–68.
29. Thomsen RW, Jepsen P, Sorensen HT. Diabetes mellitus and pyogenic liver
abscess: risk and prognosis. Clin Infect Dis. 2007;44(9):1194–201.
30. Foo NP, Chen KT, Lin HJ, Guo HR. Characteristics of pyogenic liver abscess patients
with and without diabetes mellitus. Am J Gastroenterol. 2010;105(2):328–35.
31. Chuah SK, Chang-Chien C, Sheen IS, Lin HH, Chiou SS, Chiu CT, Kuo CH,
Chen JJ, Chiu KW. The prognostic factors of severe amebic liver abscess: a
retrospective study of 125 cases. Am J Trop Med Hyg. 1992;46(4):398–402.
32. Jeong SW, Jang JY, Lee TH, Kim HG, Hong SW, Park SH, Kim SG, Cheon YK, Kim
YS, Cho YD, Kim JO, Kim BS, Lee EJ, Kim TH. Cryptogenic pyogenic liver abscess
as the herald of colon cancer. J Gastroenterol Hepatol. 2012;27:248–55.
33. Farges O, Leese T, Bismuth PH. Pyogenic liver abscess: an improvement in
prognosis. Br J Surg. 1988;75(9):862–5.
34. Du ZQ, Zhang L, Lu Q, Ren YF, Lv Y, Liu XM, Zhang XF. Clinical
characteristics and outcome of pyogenic liver abscess with different size:
15-year experience from a single center. Sci Rep. 2016;6:35890.
35. Heneghan HM, Healy NA, Martin ST, Ryan RS, Nolan N, Traynor O, Waldron
R. Modern management of pyogenic hepatic abscess: a case series and
review of the literature. BMC Res Notes. 2011;4(1):80.
Neill et al. BMC Infectious Diseases          (2019) 19:490 Page 7 of 8
36. Su YJ, Lai YC, Lin YC, Yeh YH. Treatment and prognosis of pyogenic liver
abscess. Int J Emerg Med. 2010;3(4):381–4.
37. O'Farrell N, Collins CG, McEntee GP. Pyogenic liver abscesses: diminished
role for operative treatment. Surgeon. 2010;8(4):192–6.
38. Czerwonko ME, Huespe P, Bertone S, Pellegrini P, Mazza O, Pekolj J, de
Santibañes E. Pyogenic liver abscess: current status and predictive factors
for recurrence and mortality of first episodes. HPB. 2016;8(12):1023–30.
39. Zhu X, Wang S, Jacob R, Fan Z, Zhang F, Ji G. A 10-year retrospective
analysis of clinical profiles, laboratory characteristics and Management of
Pyogenic Liver Abscesses in a Chinese hospital. Gut Liver. 2011;5(2):221–7.
40. Santos-Rosa OM, Lunardelli H, Ribeiro-Junior MAF. Pyogenic liver abscess:
diagnostic and therapeutic management. Arg Bras Cir Dig. 2016;29(3):194–7.
41. Chen CH, Wu SS, Chang HC, Chang YJ. Initial presentations and final
outcomes of primary pyogenic liver abscess: a cross-sectional study. BMC
Gastroenterol. 2014;41(1):133.
42. Chen SC, Tsai SJ, Chen CH, Huang CC, Lin DB, Wang PH, Chen CC, Lee MC.
Predictors of mortality in patients with pyogenic liver abscess. Neth J Med.
2008;66:196–203.
43. Chen WH, Chiu CH, Huang CH, Lin CH, Sun JH, Huang YY, Wang CC.
Pyogenic liver abscess caused by pseudomonas aeringosa: clinical analysis
of 20 cases. Scand J Infect Dis. 2011;43(11–12):877–82.
44. Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen FC, Tai DI. Prognostic
factors for pyogenic abscess of the liver. J Am Coll Surg. 1994;179:727–32.
45. Lee KT, Sheen PC, Chen JS, Ker CG. Pyogenic liver abscess: multivariate
analysis of risk factors. World J Surg. 1991;15(3):372–6.
46. Mischinger HJ, Hauser H, Rabl H, Quehenberger F, Werkgartner G, Rubin R,
Due E. Pyogenic liver abscess: studies of therapy and analysis of risk factors.
World J Surg. 1994;18:852–7.
47. Yeh TS, Jan YY, Jeng LB, Hwang TL, Chao TC, Chien RN, Chen MF. Pyogenic
liver abscesses in patients with malignant disease: a report of 52 cases
treated at a single institution. Arch Surg. 1998;133(3):242–5.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Neill et al. BMC Infectious Diseases          (2019) 19:490 Page 8 of 8
